Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QLF31907 injection in advanced melanoma and advanced urothelial carcinoma
CTR20230802Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QLF31907 in melanoma, transitional cell carcinoma (TCC), sponsored by Qilu Pharmaceutical. Started Apr 2023; status: active.
02
Drugs
QLF31907
03
Conditions
melanomatransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20230802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230802.